Ohtuvayre

Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product in COPD alone, its potential extends to other respiratory disorders as well.

By Frank Vinluan

BioPharma

Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD

Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. Verona executives contend their inhalable drug has key advantages over the last novel COPD medication, the orally administered roflumilast.

By Frank Vinluan